Science Explorer Back to mapMap
Discussion
Topic · Epidemiology

Inflammatory Myopathies and Dermatomyositis

Inflammatory Myopathies and Dermatomyositis is a research topic within Epidemiology. Science Explorer counts 17k research works in it since 1950. 10.2% of them reached the world's top 10% most cited for their field and year.

This cluster of papers covers the epidemiology, classification, and clinical features of inflammatory myopathies such as dermatomyositis and polymyositis. It includes discussions on autoantibodies, interstitial lung disease, cancer risk, treatment strategies, myositis-specific antibodies, juvenile dermatomyositis, and the association with malignancy.

  • Inflammatory Myopathies
  • Dermatomyositis
  • Polymyositis
  • Autoantibodies
  • Interstitial Lung Disease
  • Cancer Risk
  • Treatment
  • Myositis-specific Antibodies
  • Juvenile Dermatomyositis
  • Malignancy
Research works
17k
fractional, since 1950
In the world top 10%
1.8k
per year above
Top-10% rate
10.2%
share of its works in the world top 10%
Growth, 2018-21 → 2022-25
+26%
the tick is no change
Largest producer
United States
31% of the 10 largest, 2022-now
Inflammatory Myopathies and Dermatomyositis

This ranks research output and citation impact. It says nothing about the quality of diagnosis, treatment or care.

Which countries lead Inflammatory Myopathies and Dermatomyositis research?

By volume, the United States and China publish the most (966 and 506 works in 2022-now).

By volume, 2022-now

  1. 1 United States 966 works
  2. 2 China 506 works
  3. 3 Japan 341 works
  4. 4 United Kingdom 238 works
  5. 5 India 224 works
  6. 6 Italy 195 works
  7. 7 France 192 works
  8. 8 Germany 155 works
  9. 9 Spain 143 works
  10. 10 Brazil 111 works

How concentrated that is

The same countries as shares of everything the list above accounts for. A node where two countries do two thirds of the work and one spread evenly across twelve read alike as a ranking and not at all alike here.

United States: 31.5%China: 16.5%Japan: 11.1%United Kingdom: 7.8%6 others listed: 33.2%31%largest
United States966 · 31.5%China506 · 16.5%Japan341 · 11.1%United Kingdom238 · 7.8%6 others listed1,021 · 33.2%

Shares of the rows listed above, not of the whole node.

Which institutions lead Inflammatory Myopathies and Dermatomyositis research?

By volume in 2022-now, Johns Hopkins University publishes the most Inflammatory Myopathies and Dermatomyositis research, followed by Harvard University and Mayo Clinic.

By volume, 2022-now

  1. 1 Johns Hopkins UniversityUnited States 45 works
  2. 2 Harvard UniversityUnited States 35 works
  3. 3 Mayo ClinicUnited States 34 works
  4. 4 Shanghai Jiao Tong UniversityChina 28 works
  5. 5 University of PennsylvaniaUnited States 27 works
  6. 6 All India Institute of Medical SciencesIndia 27 works
  7. 7 InsermFrance 27 works
  8. 8 Universidade de São PauloBrazil 25 works
  9. 9 University College LondonUnited Kingdom 24 works
  10. 10 Sichuan UniversityChina 23 works

Who are the leading researchers in Inflammatory Myopathies and Dermatomyositis?

The most-cited researchers publishing on Inflammatory Myopathies and Dermatomyositis include John P. A. Ioannidis, Gordon Henry Guyatt and Gregory Y.H. Lip.

  1. 1 John P. A. Ioannidis United States 317k citations
  2. 2 Gordon Henry Guyatt Canada 315k citations
  3. 3 Gregory Y.H. Lip United Kingdom 311k citations
  4. 4 Isabelle Boutron France 271k citations
  5. 5 Jean‐Louis Vincent Belgium 262k citations

Ranked by citations received across their whole record, among researchers with at least three works on this topic.

What are the most cited papers in Inflammatory Myopathies and Dermatomyositis?

The most cited paper in Inflammatory Myopathies and Dermatomyositis is "Polymyositis and Dermatomyositis" (Anthony Bohan, James B. Peter, 1975), with 5,137 citations. Next come "Preliminary criteria for the classification of systemic sclerosis (scleroderma)" (4,957) and "2013 Classification Criteria for Systemic Sclerosis: An American College of Rheumatology/European League Against Rheumatism Collaborative Initiative" (3,458).

Most cited papers
#PaperReleasedCitations
1 Polymyositis and Dermatomyositis Anthony Bohan, James B. Peter · New England Journal of Medicine 13 Feb 1975 5,137
2 Preliminary criteria for the classification of systemic sclerosis (scleroderma) Alfonse T. Masi · Arthritis & Rheumatism May 1980 4,957
3 2013 Classification Criteria for Systemic Sclerosis: An American College of Rheumatology/European League Against Rheumatism Collaborative Initiative Frank H J van den Hoogen et al. · Arthritis & Rheumatism Open access 3 Oct 2013 3,458
4 Mixed connective tissue disease-an apparently distinct rheumatic disease syndrome associated with a specific antibody to an extractable nuclear antigen (ENA) Gordon C. Sharp, William S. Irvin, Eng M. Tan et al. · The American Journal of Medicine Feb 1972 1,855
5 Nintedanib for Systemic Sclerosis–Associated Interstitial Lung Disease Oliver Distler, Kristin B. Highland, Martina Gahlemann et al. · New England Journal of Medicine Open access 20 May 2019 1,667
All 97 most cited papers, with filters and sorting

Where is Inflammatory Myopathies and Dermatomyositis research done?

The largest centres of Inflammatory Myopathies and Dermatomyositis research in 2022-now are Beijing (China), Tokyo (Japan), Paris (France) and London (United Kingdom). Among places with at least 20 works in it, it is an unusually large share of all research in Tunis.

Largest cities, 2022-now

  1. 1 BeijingChina 97 works
  2. 2 TokyoJapan 94 works
  3. 3 ParisFrance 79 works
  4. 4 LondonUnited Kingdom 69 works
  5. 5 BaltimoreUnited States 51 works
  6. 6 ShanghaiChina 48 works
  7. 7 PhiladelphiaUnited States 47 works
  8. 8 São PauloBrazil 43 works
  9. 9 New YorkUnited States 41 works
  10. 10 SeoulSouth Korea 38 works

Where it is the local speciality

  1. TunisTN · 23.3 works8.3×
← less than its size predicts1×more →

Location quotient: how much more of its research is in Inflammatory Myopathies and Dermatomyositis than the world average.

See Inflammatory Myopathies and Dermatomyositis on the map

Where is the best place to study Inflammatory Myopathies and Dermatomyositis?

Among universities, judged by research, Johns Hopkins University, Harvard University and Humanitas University score highest, combining excellence, specialisation, size, growth and international reach. Research strength is one signal when choosing where to study; it does not measure teaching.

0%20%40%mean 19.04%fractional works in this field (log) →share of work in the world top 10% →Humanitas UniversityJohns Hopkins Univer…Harvard UniversityKarolinska Institutet
above the meannear itbelow it

One dot per university in the first ten of the table below, at the default weights. The upper left is the interesting corner: small places doing unusually strong work.

Excellenceshare of its work in the world top 10%, 2022-now and all time averaged
40%
Specialisationhow much of its work is in this field, counted up to 10× the world share
10%
Sizeits output in this field, on a log scale
30%
Growthoutput growth, counted from -20% to +20%
10%
Internationalshare of its work with a co-author abroad
10%
Each slider sets a weight; the share it gets of the score is beside it.
#UniversityScoreTop 10%SpecialisationWorksGrowth
1Johns Hopkins UniversityUnited States 76.618.0%7.9×45 +35.4%
2Harvard UniversityUnited States 63.415.4%3.0×35 +20.8%
3Humanitas UniversityItaly 62.540.5%15.9×9 -
4Karolinska InstitutetSweden 57.214.0%9.3×20 -9.9%
5University of PaduaItaly 55.828.0%5.0×15 +105.0%
6University of PennsylvaniaUnited States 53.510.2%6.9×27 +25.3%
7University College LondonUnited Kingdom 52.115.8%4.0×24 -8.4%
8Sichuan UniversityChina 52.121.5%2.7×23 +223.1%
9University of PittsburghUnited States 51.816.8%4.7×14 +19.0%
10Shanghai Jiao Tong UniversityChina 49.110.2%2.6×28 +97.8%

Universities only. The score blends excellence (40%), size (30%), specialisation (10%), growth (10%), international reach (10%), 2022-now; growth compares 2018-21 with 2022-25 and counts up to +20%, since a jump from a small base is mostly noise.

Every institution in Inflammatory Myopathies and Dermatomyositis, country by country

Is Inflammatory Myopathies and Dermatomyositis research growing?

Output in 2022-2025 was 26% higher than in 2018-2021, peaking in 2025. The fastest-growing topics are Inflammatory Myopathies and Dermatomyositis.

still counting19801990200020102020
grewheldshrank

The same series as a ribbon: one cell per year, darker for more. The line above answers how much; this answers when.

Its share of all research

Growing output can still be a shrinking share: all of science grows. This is Inflammatory Myopathies and Dermatomyositis as a percentage of every work published that year, 0.016% in 2024.

still counting0.010%0.020%0.030%Inflammatory Myopathies and Dermatomyositis0.019% in 202519801990200020102020

Fractional works of Inflammatory Myopathies and Dermatomyositis over all fractional works that year. How the balance of science has shifted.

How much of it reaches the world top 10%

Year by year.

still counting5%10%15%Inflammatory Myopathies and Dermatomyositis10.2% in 2025200020102020

Of each year's works in it, the share that reached the world's 10% most cited for their field and year. A field is the world for its own topics, so there is no other line to hold it against.

Which topics inside it are moving

Growth and decline on one axis around a shared zero. Two lists side by side hide the thing that matters: whether the growth dwarfs the decline, or the other way round.

Discussion

Ask a question or share a note about Inflammatory Myopathies and Dermatomyositis. Posts are plain text and can be reported.